Tocagen Inc

Tocagen — Forte Biosciences — Investor Presentation (August 2022)

13 slides from Tocagen's investor presentation, Aug 15, 2022

  1. Slide 1: Forte Biosciences Corporate Presentation August 2022

    Forte biosciences Developing treatments for Autoimmune diseases Corporate PRESENTATION AUGUST 2022 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, known as the PSLRA. These inc

  3. Slide 3: Summary of Forte Biosciences

    Summary OF Forte Biosciences: POTENTIAL first-in-class biotherapeutic for the treatment of Autoimmune diseases Examples of large market with unmet need Graft-vs-Host-Disease (GvHD)/Transplant Rejection Chronic GvHD is on the rise with the increased use of allogeneic hematopoietic stem cell transplan

  4. Slide 4: Overview of FB-102 Therapeutic Molecule

    FORTE BIOSCIENCES: Overview of FB-102 Therapeutic Molecule Antagonism of pathway for autoimmune disease Proprietary molecule Multibillion dollar revenue potential Preclinical PoC validates target Significant unmet need in autoimmune diseases including potentially graft-vs-host disease / transplant r

  5. Slide 5: Experienced management

    EXPERIENCED management Paul Wagner, PhD, CFA – CEO Forte’s management has extensive experience in manufacturing, quality, and regulatory and clinical development in autoimmune disorders Tony Riley, CPA – Chief Financial Officer Chris Roenfeldt – Chief Operating Officer Steven Ruhl – Chief Technical

  6. Slide 6: Experienced Scientific Advisory Board

    EXPERIENCED Scientific Advisory Board Scientific Advisory Board (SAB) Steve Doberstein, PhD – Former Head of Research and Development at Nektar Therapeutics Prof. Lawrence Eichenfield, MD – Chief of Pediatric and Adolescent Dermatology at Rady Children's Hospital-San Diego, Editor in Chief of Pediat

  7. Slide 7: Board with extensive public company experience

    BOARD with extensive public company experience Board with strong track record at public companies Steve Doberstein, PhD – Former Head of Research and Development at Nektar Therapeutics Prof. Lawrence Eichenfield, MD – Chief of Pediatric and Adolescent Dermatology at Rady Children's Hospital-San Dieg

  8. Slide 8: Graft-vs-Host-Disease/Transplant rejection overview

    Graft-vs-Host-Disease/Transplant rejection overview Graft-versus-host disease (GvHD) is a common potentially life-threatening complication associated with allogeneic hematopoietic stem cell transplantation (HSCT) in which the transplanted cells initiate an immune response against the transplant reci

  9. Slide 9: Vitiligo overview

    Vitiligo overview Vitiligo is characterized by the loss of melanocytes which are cells that produce skin pigmentation Vitiligo results in discolored patches appearing in the skin, hair and mucous membrane Vitiligo is an autoimmune disease in which the immune system attack melanocytes It is estimated

  10. Slide 10: Alopecia Areata overview

    Alopecia Areata overview Alopecia Areata (AA) is characterized by nonscarring hair loss generally on the scalp but can also other areas of the body AA is an autoimmune disease in which immune cells attack and damage hair follicles There remains a significant unmet need for safe and effective therapi

  11. Slide 11: FB-102 has potential in several other autoimmune diseases

    FB-102 has potential in several other autoimmune diseases Eosinophilic esophagitis Atopic Dermatitis Celiac Disease Type 1 Diabetes Ulcerative colitis Non-Alcoholic Steatohepatitis (NASH)

  12. Slide 12: Pipeline

    Pipeline Asset Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 FB-102 GvHD Vitiligo Alopecia Areata Celiac Disease Forte expects FB-102 to be in the clinic in the late 2023/early 2024

  13. Slide 13: Summary of Forte Biosciences

    Summary OF Forte Biosciences: POTENTIAL first-in-class biotherapeutic for the treatment of Autoimmune diseases Examples of large market with unmet need Graft-vs-Host-Disease (GvHD)/Transplant Rejection Chronic GvHD is on the rise with the increased use of allogeneic hematopoietic stem cell transplan

Forte Biosciences — Investor Presentation (August 2022) on 6ix